Maxim Group reiterated their buy rating on shares of Biopharmx Corp (NASDAQ:BPMX) in a research note released on Wednesday morning, Marketbeat Ratings reports. Maxim Group currently has a $1.50 target price on the stock, down from their prior target price of $3.00.
Several other analysts also recently commented on the company. HC Wainwright reissued a buy rating and issued a $3.00 price objective on shares of Biopharmx Corp in a research note on Wednesday. Roth Capital set a $3.00 price objective on Biopharmx Corp and gave the stock a buy rating in a research note on Saturday, June 3rd.
Biopharmx Corp (BPMX) traded up 6.087% on Wednesday, reaching $0.305. The company’s stock had a trading volume of 542,089 shares. Biopharmx Corp has a 52-week low of $0.19 and a 52-week high of $0.90. The company’s market cap is $22.61 million. The firm’s 50-day moving average price is $0.31 and its 200 day moving average price is $0.48.
Biopharmx Corp (NASDAQ:BPMX) last issued its quarterly earnings data on Wednesday, September 13th. The company reported ($0.06) EPS for the quarter, hitting the consensus estimate of ($0.06). The firm had revenue of $0.02 million during the quarter, compared to the consensus estimate of $0.02 million. Biopharmx Corp had a negative return on equity of 1,847.04% and a negative net margin of 28,405.26%. Equities analysts anticipate that Biopharmx Corp will post ($0.25) EPS for the current fiscal year.
TRADEMARK VIOLATION WARNING: This story was posted by Chaffey Breeze and is owned by of Chaffey Breeze. If you are reading this story on another publication, it was copied illegally and reposted in violation of US and international copyright legislation. The legal version of this story can be read at https://www.chaffeybreeze.com/2017/09/17/biopharmx-corp-bpmx-receives-buy-rating-from-maxim-group.html.
In other Biopharmx Corp news, major shareholder Franklin Resources Inc bought 250,000 shares of Biopharmx Corp stock in a transaction dated Tuesday, August 1st. The stock was bought at an average cost of $0.34 per share, with a total value of $85,000.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.
Several hedge funds have recently added to or reduced their stakes in BPMX. Vanguard Group Inc. grew its holdings in shares of Biopharmx Corp by 324.6% in the second quarter. Vanguard Group Inc. now owns 1,933,747 shares of the company’s stock valued at $927,000 after acquiring an additional 1,478,338 shares in the last quarter. Vivo Capital LLC grew its holdings in Biopharmx Corp by 10.0% during the second quarter. Vivo Capital LLC now owns 14,096,338 shares of the company’s stock valued at $6,752,000 after purchasing an additional 1,282,052 shares during the period. Finally, Virtu KCG Holdings LLC grew its holdings in Biopharmx Corp by 366.2% during the second quarter. Virtu KCG Holdings LLC now owns 503,418 shares of the company’s stock valued at $241,000 after purchasing an additional 395,424 shares during the period.
About Biopharmx Corp
BioPharmX Corporation is a specialty pharmaceutical company. The Company is focused on utilizing its drug delivery technologies to develop and commercialize prescription and over-the-counter (OTC) products that address markets in women’s health and dermatology. Its portfolio of product candidates includes two clinical stage product candidates: BPX01, which is a topical antibiotic for the treatment of acne based on a formulation of minocycline, and BPX03, which is a molecular iodine (I2) tablet for the treatment of benign breast pain associated with fibrocystic breast condition (FBC) and cyclic mastalgia.
Receive News & Ratings for Biopharmx Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biopharmx Corp and related companies with MarketBeat.com's FREE daily email newsletter.